In the past decade, studies reported that many molecules with RGD-modification can efficiently deliver drugs to tumor vasculature endothelium.Our lab (Xu et al.) introduced the integrin-binding RGD into peptide ES-2 sequence and found that the RGD-modified synthetic peptide, designated as HM-3, displayed significant anti-tumor activity in animal models.Safety experiments showed no evidence of toxicity in the treated animals.These indicate that HM-3 is an effective and safe anti-tumor drug.We have finished all of preclinical experients and will applying for clinical research authorization.